Previous 10 | Next 10 |
Agenus Inc. (AGEN) Q1 2021 Earnings Conference Call May 06, 2021 8:30 AM ET Company Participants John Medina – Director-Investor Relations Garo Armen – Chairman and Chief Executive Officer Jennifer Buell – President and Chief Operating Officer Steven O'Day – Chief ...
Agenus (AGEN) shares fall 3% during premarket trading after the company posted first-quarter revenue that missed Wall Street estimates. The company's Q1 revenue fell 23% to $11.72M, missing analysts' average estimate by $2.81M.The company ended its first quarter 2021 with a cas...
Agenus (AGEN): GAAP EPS of -$0.27 beats by $0.04.Revenue of $11.72M (-22.5% Y/Y) misses by $2.81M.Shares +1.2% PM.Press Release For further details see: Agenus EPS beats by $0.04, misses on revenue
Balstilimab BLA submitted to FDA for recurrent/metastatic cervical cancer Balstilimab and AGEN2373 data to be presented at ASCO iNKT cell therapy Phase 1 initiated in cancer LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology c...
LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will gi...
LEXINGTON, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will re...
Agenus (AGEN) submits Biologics License Application ((BLA)) to the FDA, seeking accelerated approval of balstilimab, an anti-PD-1 antibody, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.The balstilimab BLA is based...
Submission has been made for review under the accelerated approval pathway LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvan...
AGEN1181 is an enhanced CTLA-4 inhibitor, a cancer therapy. Updated preliminary Phase 1 trial results were presented at AACR. Several types of cancer showed complete or partial responses. For further details see: Agenus 1181 New Cancer Response Data Adds To Conviction
Agenus (AGEN) announces the dosing of the first cancer patient in Phase 1 clinical trial of agenT-797, an allogeneic iNKT cell therapy, through its subsidiary, AgenTus Therapeutics. The Phase 1 trial has been initiated in hematologic cancers, with expansion into solid tumors expected to ...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...